vs
Investar Holding Corp（ISTR）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Investar Holding Corp的1.3倍（$30.3M vs $23.5M），REGENXBIO Inc.同比增速更快（43.0% vs 0.9%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 4.9%）
Investar Holding Corp是一家总部位于美国的银行控股公司，主要服务墨西哥湾沿岸地区客户，提供全面的商业及零售银行服务，包括存款产品、各类消费及商业贷款、抵押服务和财富管理解决方案，覆盖个人、中小企业及商业客户群体。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ISTR vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$23.5M
营收增速更快
RGNX
高出42.1%
0.9%
两年增速更快
RGNX
近两年复合增速
4.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.5M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 30.9% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | 0.9% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $0.50 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ISTRRGNX
| Q4 25 | $23.5M | $30.3M | ||
| Q3 25 | $24.1M | $29.7M | ||
| Q2 25 | $22.3M | $21.4M | ||
| Q1 25 | $24.0M | $89.0M | ||
| Q4 24 | $23.3M | $21.2M | ||
| Q3 24 | $22.3M | $24.2M | ||
| Q2 24 | $20.4M | $22.3M | ||
| Q1 24 | $21.4M | $15.6M |
净利润ISTRRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $6.2M | $-61.9M | ||
| Q2 25 | $4.5M | $-70.9M | ||
| Q1 25 | $6.3M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $5.4M | $-59.6M | ||
| Q2 24 | $4.1M | $-53.0M | ||
| Q1 24 | $4.7M | $-63.3M |
毛利率ISTRRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率ISTRRGNX
| Q4 25 | 30.9% | -190.0% | ||
| Q3 25 | 31.0% | -176.3% | ||
| Q2 25 | 24.4% | -296.3% | ||
| Q1 25 | 32.2% | 13.6% | ||
| Q4 24 | 31.1% | -242.1% | ||
| Q3 24 | 27.6% | -256.6% | ||
| Q2 24 | 24.0% | -251.3% | ||
| Q1 24 | 28.5% | -408.8% |
净利率ISTRRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | 25.6% | -208.3% | ||
| Q2 25 | 20.2% | -331.8% | ||
| Q1 25 | 26.3% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 24.1% | -246.3% | ||
| Q2 24 | 19.9% | -237.7% | ||
| Q1 24 | 22.0% | -405.4% |
每股收益（稀释后）ISTRRGNX
| Q4 25 | $0.50 | $-1.30 | ||
| Q3 25 | $0.54 | $-1.20 | ||
| Q2 25 | $0.46 | $-1.38 | ||
| Q1 25 | $0.63 | $0.12 | ||
| Q4 24 | $0.61 | $-0.99 | ||
| Q3 24 | $0.54 | $-1.17 | ||
| Q2 24 | $0.41 | $-1.05 | ||
| Q1 24 | $0.48 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | $9.8M | — |
| 股东权益账面价值 | $301.1M | $102.7M |
| 总资产 | $2.8B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.03× | — |
8季度趋势，按日历期对齐
现金及短期投资ISTRRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务ISTRRGNX
| Q4 25 | $9.8M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $9.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ISTRRGNX
| Q4 25 | $301.1M | $102.7M | ||
| Q3 25 | $295.3M | $161.5M | ||
| Q2 25 | $255.9M | $213.7M | ||
| Q1 25 | $251.7M | $274.2M | ||
| Q4 24 | $241.3M | $259.7M | ||
| Q3 24 | $245.5M | $301.4M | ||
| Q2 24 | $230.2M | $348.3M | ||
| Q1 24 | $227.0M | $390.7M |
总资产ISTRRGNX
| Q4 25 | $2.8B | $453.0M | ||
| Q3 25 | $2.8B | $525.2M | ||
| Q2 25 | $2.7B | $581.0M | ||
| Q1 25 | $2.7B | $490.9M | ||
| Q4 24 | $2.7B | $466.0M | ||
| Q3 24 | $2.8B | $519.1M | ||
| Q2 24 | $2.8B | $569.4M | ||
| Q1 24 | $2.8B | $629.2M |
负债/权益比ISTRRGNX
| Q4 25 | 0.03× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.2M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ISTRRGNX
| Q4 25 | $18.2M | $-52.3M | ||
| Q3 25 | $6.9M | $-56.0M | ||
| Q2 25 | $3.2M | $-49.3M | ||
| Q1 25 | $4.5M | $33.6M | ||
| Q4 24 | $15.9M | $-31.6M | ||
| Q3 24 | $5.6M | $-40.5M | ||
| Q2 24 | $2.8M | $-45.5M | ||
| Q1 24 | $7.8M | $-55.5M |
自由现金流ISTRRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率ISTRRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度ISTRRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率ISTRRGNX
| Q4 25 | — | — | ||
| Q3 25 | 1.12× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 0.71× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 1.66× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ISTR
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
